의학 뉴스 및 연구

In the 360-patient TRIC-I-HF randomized trial (mean age 80), repair cut the 3-year composite risk by 60% with 5.9% major adverse events at 30 days.

FDA approval follows a 52-week randomized, double-blind, placebo-controlled trial in 188 patients aged 2 to 21 years on background SMN2 treatment, with clinically meaningful gains in 34% vs 14% on placebo and a noted fracture risk.

Difference-in-differences analysis of 77,000 person-years in the UKHLS links UC introduction to a 0.94-point SF-12 MCS decline and a 3.8 percentage-point rise in probable depression, with larger effects in bigger families.

In the 1000-patient ARISE FLUIDS randomized trial, days alive and out of hospital were identical versus a higher-fluid strategy, while pulmonary edema was lower with early vasopressors.